- contact@cgenetix.com
- + 33 6 67 77 23 94
Healthcare Consulting Partner
The Innovative and non-invasive Alternative in personalized medicine For transplant patients
Developing the next generation of non invasive molecular biology diagnostic tool for the clinical monitoring of transplant patient.
Healthcare Consulting Partner
The Innovative and non-invasive Alternative in personalized medicine For transplant patients
Developing the next generation of non invasive molecular biology diagnostic tool for the clinical monitoring of transplant patient.
Our Vision
Improve transplant patients monitoring by giving clinicians the best tools to evaluate graft functionality in a non-invasive way.
With two major goal in mind : Improve the quality of life and care !
With two major goal in mind : Improve the quality of life and care !
During the Sars-CoV-2 pandemic
The Sars-CoV-2 pandemic revealed the lack of early identification of lung lesions during the acute respiratory failure induced by the virus.
Early recognition at hospital admission of a patient at risk of worsening of these symptoms would be of major medical benefit.
Amazed by the lack of biomarkers, we sought to help clinicians by identifying early organ damage with a simple liquid biopsy (blood/urine) sample, based on a molecular technology platform
Early recognition at hospital admission of a patient at risk of worsening of these symptoms would be of major medical benefit.
Amazed by the lack of biomarkers, we sought to help clinicians by identifying early organ damage with a simple liquid biopsy (blood/urine) sample, based on a molecular technology platform
Clinical Applications
Explore Our healthcare
consulting services
Kidney transplantation
Providing a correct diagnosis of kidney transplant rejection remains a challenge and requires invasive technologies
Lung transplantation
Providing a correct diagnosis of Lung transplant rejection remains a challenge and requires invasive technologies
Who are we?
« A complementary panel of specialists in transplantation, supported by various partners to achieve our objectives of tomorrow »
You want more information about our company or you want to participate in improving patients’ medical healthcare ?
CGenetix develops the new generation of liquid biopsy biomarkers to evaluate organs damages during a pathological process.